II
TEVA icon

IFM Investors’s Teva Pharmaceuticals TEVA Stock Holding History

IFM Investors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.47M Buy
279,547
+35,183
+14% +$1.17M 0.06% 267
2026
Q1 		$7.36M Buy
244,364
+6,639
+3% +$214K 0.06% 287
2025
Q4 		$7.42M Buy
237,725
+8,293
+4% +$204K 0.06% 273
2025
Q3 		$4.21M Buy
229,432
+2,898
+1% +$50.9K 0.04% 391
2025
Q2 		$3.8M Buy
226,534
+19,447
+9% +$314K 0.04% 405
2025
Q1 		$3.18M Hold
207,087
– – 0.03% 430
2024
Q4 		$4.56M Sell
207,087
-23,941
-10% -$436K 0.05% 353
2024
Q3 		$4.16M Buy
231,028
+8,285
+4% +$145K 0.04% 397
2024
Q2 		$3.62M Buy
222,743
+8,702
+4% +$134K 0.04% 411
2024
Q1 		$3.02M Buy
214,041
+30,270
+16% +$382K 0.03% 450
2023
Q4 		$1.92M Hold
183,771
– – 0.02% 501
2023
Q3 		$1.87M Buy
183,771
+5,075
+3% +$47.3K 0.02% 516
2023
Q2 		$1.35M Buy
178,696
+9,821
+6% +$79.6K 0.02% 568
2023
Q1 		$1.49M Buy
168,875
+2,041
+1% +$20.2K 0.02% 546
2022
Q4 		$1.52M Sell
166,834
-1,825
-1% -$15.9K 0.03% 521
2022
Q3 		$1.36M Buy
168,659
+3,313
+2% +$29.3K 0.02% 528
2022
Q2 		$1.24M Hold
165,346
– – 0.02% 546
2022
Q1 		$1.55M Buy
165,346
+30,190
+22% +$252K 0.02% 527
2021
Q4 		$1.08M Hold
135,156
– – 0.02% 571
2021
Q3 		$1.32M Buy
135,156
+919
+0.7% +$8.61K 0.03% 531
2021
Q2 		$1.33M Hold
134,237
– – 0.03% 554
2021
Q1 		$1.55M Buy
134,237
+36,934
+38% +$424K 0.04% 438
2020
Q4 		$939K Sell
97,303
-1,652
-2% -$15.8K 0.03% 511
2020
Q3 		$892K Buy
98,955
+11,680
+13% +$124K 0.04% 434
2020
Q2 		$1.08M Sell
87,275
-47,562
-35% -$538K 0.06% 329
2020
Q1 		$1.15M Buy
134,837
+47,649
+55% +$488K 0.05% 349
2019
Q4 		$854K Sell
87,188
-1,352
-2% -$12.1K 0.03% 511
2019
Q3 		$609K Buy
88,540
+29,740
+51% +$228K 0.02% 556
2019
Q2 		$543K Buy
58,800
+2,402
+4% +$29K 0.03% 516
2019
Q1 		$884K Hold
56,398
– – 0.06% 363
2018
Q4 		$870K Buy
56,398
+6,275
+13% +$129K 0.07% 287
2018
Q3 		$1.08M Buy
50,123
+6,823
+16% +$158K 0.08% 247
2018
Q2 		$1.05M Buy
43,300
+14,960
+53% +$305K 0.1% 215
2018
Q1 		$484K Buy
28,340
+3,089
+12% +$60.3K 0.07% 320
2017
Q4 		$479K Hold
25,251
– – 0.08% 299
2017
Q3 		$444K Buy
25,251
+528
+2% +$11.9K 0.07% 306
2017
Q2 		$821K Buy
24,723
+6,314
+34% +$195K 0.15% 163
2017
Q1 		$591K Buy
18,409
+6,853
+59% +$234K 0.15% 162
2016
Q4 		$419K Buy
+11,556
New +$461K 0.2% 131

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

IFM Investors's TEVA Position: Q2 2026 in Review

IFM Investors increased its Teva Pharmaceuticals (TEVA) stake by 14% in Q2 2026, buying an estimated $1.17M and bringing the position to 279,547 shares worth $9.47M. The position accounts for 0.06% of the portfolio, ranked #267.

IFM Investors first reported a position in TEVA in Q4 2016 and has held it in 39 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • IFM Investors held 279,547 shares of Teva Pharmaceuticals worth $9.47M as of Q2 2026.
  • IFM Investors bought 35,183 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
  • Teva Pharmaceuticals made up 0.06% of IFM Investors's portfolio in Q2 2026, its #267 holding.
  • IFM Investors first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.